Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma

Q2 FY24 Financial Press Release Source link

Q3 FY23 Financial Press Release Source link

Q4 FY23 Financial Press Release Source link

Sun Pharma and Zydus sign licensing agreement for co-marketing of Desidustat in India Source link

Sun Pharma to announce second quarter results on November 01, 2023 Source link

CEQUA® (cyclosporine ophthalmic solution) 0.09% Phase 4 Data Showed Sustained Improvement in Dry Eye Disease Signs and Symptoms in Patients...